Answers are grounded in this paper and cite their sources.
Young women serve less frequently than young men as subjects in premarketing clinical drug trials. Moral, legal, and medical implications of this underrepresentation of women are considered. Risks of medical harm to female patients can increase because medication is withheld. Also, risks of toxicity increase when women receive certain new drugs only in the postmarketing phase. Remedies to increase participation of young, nonpregnant women in clinical trials are discussed.
No takes yet. Share an insight, caveat, or question.
Kinney et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: